Kidney Cancer

Latest News

Study to evaluate DF9001 plus pembrolizumab in solid tumors, including RCC
Study to evaluate DF9001 plus pembrolizumab in solid tumors, including RCC

May 22nd 2024

The first-in-human study expects to begin dosing patients with DF9001 in combination with pembrolizumab in Q4 of 2024.

Dosing commences in phase 1/2 trial of AB-2100 in ccRCC
Dosing commences in phase 1/2 trial of AB-2100 in ccRCC

May 15th 2024

Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
Grant awarded to aid development of allogeneic CAR T treatment for RCC

April 29th 2024

siRNA drug therapy shows promise in clear cell renal cell carcinoma
siRNA drug therapy shows promise in clear cell renal cell carcinoma

April 25th 2024

Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC

April 19th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.